Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acurx PharmaceuticalsFRA:3ZO0 35 FCF Yield % is -100.69 as of Jul. 27, 2026. GuruFocus rates FRA:3ZO0 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,407 Biotechnology companies, Acurx Pharmaceuticals ranks worse than 89.77% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Acurx Pharmaceuticals FCF Yield % Related Terms
Acurx Pharmaceuticals FCF Yield % Historical Data
* Premium members only.
The historical data trend for Acurx Pharmaceuticals's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3ZO0 vs KAPA, PULM, ADIL: FCF Yield % Comparison
For the Biotechnology subindustry, Acurx Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acurx Pharmaceuticals FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Acurx Pharmaceuticals's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acurx Pharmaceuticals (FRA:3ZO0) has a FCF Yield % of -100.69 as of Jul. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Acurx Pharmaceuticals and its competitors. According to the industry distribution chart, Acurx Pharmaceuticals ranks #1263 out of 1407 companies in the Biotechnology industry, placing it in the top 89.8%.
Is Acurx Pharmaceuticals' FCF Yield % too high?
Acurx Pharmaceuticals' current FCF Yield % is -100.69. Based on the distribution chart, Acurx Pharmaceuticals ranks #1263 out of 1407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acurx Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' FCF Yield % compare to KAPA and PULM?
According to the Biotechnology industry distribution chart, Acurx Pharmaceuticals ranks #1263 out of 1407 companies for FCF Yield %. This places Acurx Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Acurx Pharmaceuticals and its competitors. Acurx Pharmaceuticals's current FCF Yield % is -100.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (FRA:3ZO0) has a current FCF Yield % of -100.69. The current FCF Yield % is -100.69. Acurx Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Acurx Pharmaceuticals (FRA:3ZO0), the current FCF Yield % is -100.69 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
35GF Score
Get the complete analysis for FRA:3ZO0
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3ZO0 has been successfully added to your 
